You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed or refractory Hodgkin's Disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
Oct 31, 2022

Hodgkin Lymphoma Trial in Salt Lake City (Axatilimab, Nivolumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Feb 1, 2023

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    National Research Center for Hematology
Dec 13, 2022

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

Not yet recruiting
  • Hodgkin Lymphoma
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Aug 18, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Pembrolizumab plus Chemotherapy (ICE or DHAP))

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab plus Chemotherapy (ICE or DHAP)
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)

Recruiting
  • T-lymphoblastic Lymphoma
  • +5 more
  • BCL2 Inhibitor plus IM2 regimen
  • Shanghai, Shanghai, China
    Shanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

Recruiting
  • Relapsed/Refractory Classical Hodgkin Lymphoma
  • Brentuximab vedotin
  • Goyang, Gyeonggi-do, Korea, Republic of
    Hyeon-Seok Eom
Feb 12, 2022

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma Trial in Stanford (Magrolimab, Pembrolizumab,

Recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Stanford, California
    Stanford University
Jun 21, 2022

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Lymphoma, Non-Hodgkin, Hodgkin Lymphoma Trial in Worldwide (AZD3470)

Not yet recruiting
  • Lymphoma
  • +2 more
  • Miami, Florida
  • +10 more
Nov 13, 2023

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Russian Federation
  • +1 more
Mar 3, 2023

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022